

Ref: NLL\CS\2012-52

May 29, 2012

1. National Stock Exchange of India Limited
'G' Block, Exchange Plaza, Bandra Kurla Complex,
Bandra (East), MUMBAI – 400 051.
2. Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI – 400 001.

Sub. Investors Information Release

Dear Sirs,

Please find attached herewith an Investor Information release that "NecLife granted 'Certificate of Suitability' for Cefuroxime Sodium (Sterile) in European Union."

This is for your information and necessary dissemination to investors.

Thanking you,

Yours faithfully,
For Nectar Lifesciences Limited



(Dinesh Dua)
CEO & Director

NECTAR LIFESCIENCES LIMITED

Sco 38-39, Sector 9 D, Madhya Marg, Chandigarh 160009, U.T., India

For immediate release

NecLife granted 'Certificate of Suitability' for Cefuroxime Sodium (Sterile) in European Union.


Chandigarh, May 29, 2012

Nectar Lifesciences Limited (NecLife) a leading integrated pharmaceutical organization in India has been granted 'Certificate of Suitability' (No RO-CEP 2011-062-Rev 00) for its key sterile (injectable) molecule Cefuroxime Sodium in European Union (EU). NecLife already has EU cGMP approval for Cefuroxime Sodium, which was granted in Oct'11.

Cefuroxime Sodium is marketed by Innovator GSK as ZINACEF™ in EU & US as injectable is a USD 500 million molecule globally, of which, European sales constitute approximately 35% (USD 175 million). This translates into a significant opportunity for the Company as NecLife is indisputably one of the largest global player in cephalosporins which includes Cefuroxime sodium (Sterile) in terms of production capacity for APIs.

NecLife has already developed formulations for Cefuroxime inj. (750 mg & 1.5 g) & has already filed ANDA for US & will very soon file MAA in EU in current financial year.

Mr. Dinesh Dua, CEO & Director of NecLife said: *"The 'Certificate of Suitability' grant for Cefuroxime Sodium (Sterile) in the EU is a testimony to the efforts made by the Company to increase our reach and further entrench presence in the regulated markets. We believe we are well poised to take advantage of the opportunities the new markets have to offer. We are also confident of our ability to further augment our position in the cephalosporin market in three major molecules and are making stable progress towards securing approvals in other key markets whilst delivering healthy growth."*



About Nectar Lifesciences Limited (NecLife)

Established in 1995, NecLife (BSE code: 532649, NSE Id: NECLIFE, ISIN Id: INE023H01027) is a leading integrated pharmaceutical organization in India, offering a specialized comprehensive range of oral and sterile cephalosporin and semi-synthetic penicillin active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs). The Company is growing presence in empty hard gelatine capsules (EHGCs) and menthol products. NecLife is one of the largest manufacturers of cephalosporin range of products and has an established brand presence in 20 states across India and 50 countries across five continents. NecLife has a global leadership position in 2 oral molecules and global No. 2 position in one sterile molecule. The Company has 11 manufacturing facilities – eight in Derabassi, Punjab (API and menthol units), two in Baddi, Himachal Pradesh (FDF and EHGC plants) and one in Jammu (menthol plant). NecLife's products include Oral and sterile cephalosporin, semisynthetic, penicillin and other non-cephalosporin APIs, FDFs, Empty hard gelatin capsules and Menthol and allied products.

Additional information on NecLife is available on the Company website www.neclife.com.

Investor contacts

Dinesh Dua

Nectar Lifesciences Limited

Phone: +91 172 304 7766

Fax: +91 172 503 3537

Email: dinesh.dua@neclife.com

Note: This document contains 'forward-looking' statements at places. The Company has operations across several segments of business and remains subject to undetermined contingencies and risks. Nectar Lifesciences would not be liable for any action undertaken based on such 'forward-looking' statements and does not commit to revising/updating them publicly.

